Long Term DAPT Extension Consideration Tool
Clinical assessment
Review timing, DAPT tolerance, ischemic features, bleeding concerns, and anticoagulation status.
Clinical context
For ACS patients who are not at high bleeding risk, aspirin plus an oral P2Y12 inhibitor for at least 12 months is the default strategy. Beyond 12 months, extension may be considered in selected patients after weighing recurrent ischemic events against bleeding and incorporating patient preference.
How to interpret this checklist
- Use the result to prompt a structured clinical review, not to mandate continuation or discontinuation.
- Prior MI, multivessel disease, diabetes, CKD, LV dysfunction, PAD, and prior stent thrombosis may inform ischemic risk, but this tool does not assign validated weights.
- Bleeding flags are intentionally prompts only. Confirm formal ARC-HBR criteria using complete clinical and laboratory information; consider validated tools such as the DAPT score or PRECISE-DAPT when appropriate.
- When long-term oral anticoagulation is indicated, avoid treating prolonged triple therapy as the default; antithrombotic strategy depends on time from PCI/ACS and individual thrombotic risk.
Important limitation
The checklist categories and thresholds are pragmatic and have not been prospectively validated. It does not estimate absolute risk, NNT, NNH, or treatment effect and does not replace cardiology review or local guidelines.
Selected references
Rao SV, et al. J Am Coll Cardiol. 2025;85:2135–2237. doi:10.1016/j.jacc.2024.11.009
Virani SS, et al. J Am Coll Cardiol. 2023. doi:10.1016/j.jacc.2023.04.003
Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–2166. doi:10.1056/NEJMoa1409312
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.